US2020390931A1PendingUtilityA1

Antimicrobial wound closure materials, including antimicrobial sutures, and method for closing a wound using the same

54
Assignee: CORMEDIX INCPriority: Aug 18, 2015Filed: Dec 31, 2019Published: Dec 17, 2020
Est. expiryAug 18, 2035(~9.1 yrs left)· nominal 20-yr term from priority
Inventors:Robert DiluccioZ. Paul LorencRandy Milby
A61L 17/105A61L 2300/404A61L 17/08A61L 31/16A61P 31/04A61L 17/005A61B 2017/00889A61B 2017/06176A61L 17/10A61P 17/02A61B 17/064A61B 17/06166A61B 2017/00526A61L 17/12A61L 17/04Y02A50/30
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An antimicrobial suture comprising a filament and taurolidine.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An antimicrobial suture comprising at least one filament and taurolidine carried by said at least one filament. 
     
     
         2 . An antimicrobial suture according to  claim 1  wherein said at least one filament comprises a single filament. 
     
     
         3 . An antimicrobial suture according to  claim 1  wherein said at least one filament comprises a plurality of filaments. 
     
     
         4 . An antimicrobial suture according to  claim 3  wherein said plurality of filaments adhere to one another so as to constitute a singular structure. 
     
     
         5 . An antimicrobial suture according to  claim 4  wherein said plurality of filaments are co-extruded so as to form a composite structure. 
     
     
         6 . An antimicrobial suture according to  claim 4  wherein said plurality of filaments are braided together so as to constitute a singular structure. 
     
     
         7 . An antimicrobial suture according to  claim 1  wherein said at least one filament is resorbable. 
     
     
         8 . An antimicrobial suture according to  claim 1  wherein said at least one filament is non-resorbable. 
     
     
         9 . An antimicrobial suture according to  claim 1  wherein said at least one filament comprises a polymer. 
     
     
         10 . An antimicrobial suture according to  claim 9  wherein said at least one filament comprises a homopolymer. 
     
     
         11 . An antimicrobial suture according to  claim 1  wherein said at least one filament comprises a copolymer. 
     
     
         12 . An antimicrobial suture according to  claim 1  wherein said at least one filament comprises a material selected from the group consisting of polyglycolide (PGA), poly(glycolide-lactide) random copolymer (Vicryl®), poly-ρ-dioxanone (PDS®, PDSII®), poly(glycolide-trimethylene carbonate block copolymer (Maxon®), poly(glycolide-e-caprolactone)(Monocryl®), glycolide-dioxanone-trimethylene carbonate triblock copolymer (Biosyn®), polyethylene, polypropylene, poly(tetrafluroethylene)(Gore-Tex®), stainless steel, polyesters, polyester-ethers, polyester-carbonates, polyamides, polyolephins, fluoropolymers, catgut, collagen, reconstituted collagen, cotton, linen and silk. 
     
     
         13 . An antimicrobial suture according to  claim 1  wherein said at least one filament comprises a matrix of material. 
     
     
         14 . An antimicrobial suture according to  claim 13  wherein said taurolidine is disposed within said matrix of material. 
     
     
         15 . An antimicrobial suture according to  claim 13  wherein said taurolidine is substantially evenly dispersed within said matrix of material. 
     
     
         16 . An antimicrobial suture according to  claim 13  wherein said taurolidine is restricted to one or more regions of said matrix of material. 
     
     
         17 . An antimicrobial material according to  claim 16  wherein said at least one filament is extruded, and further wherein said taurolidine is co-extruded with said at least one filament. 
     
     
         18 . An antimicrobial suture according to  claim 17  wherein said taurolidine comprises a taurolidine-containing matrix of material, and further wherein the material of said taurolidine-containing matrix of material is the same as the material of said matrix of material of said filament. 
     
     
         19 . An antimicrobial suture according to  claim 17  wherein said taurolidine comprises a taurolidine-containing matrix of material, and further wherein the material of said taurolidine-containing matrix of material is different than the material of said matrix of material of said filament. 
     
     
         20 . An antimicrobial suture according to  claim 13  wherein said taurolidine is disposed as a coating on said at least one filament. 
     
     
         21 . An antimicrobial suture according to  claim 20  wherein said coating is co-extruded with said at least one filament. 
     
     
         22 . An antimicrobial suture according to  claim 21  wherein said coating comprises a taurolidine-containing matrix of material, and further wherein the material of said taurolidine-containing matrix of material is the same as the material of said matrix of material of said filament. 
     
     
         23 . An antimicrobial suture according to  claim 21  wherein said coating comprises a taurolidine-containing matrix of material, and further wherein the material of said taurolidine-containing matrix of material is different than the material of said matrix of material of said filament. 
     
     
         24 . An antimicrobial suture according to  claim 20  further comprising an overcoating disposed on top of said coating of taurolidine. 
     
     
         25 . An antimicrobial suture according to  claim 1  wherein the antimicrobial suture comprises multiple filaments, and further wherein the taurolidine is positioned in the interstitial spaces between the filaments. 
     
     
         26 . An antimicrobial suture according to  claim 1  wherein said at least one filament is absorbent, and further wherein a taurolidine solution is introduced into said at least one filament. 
     
     
         27 . An antimicrobial suture according to  claim 1  wherein the proportion of taurolidine in the antimicrobial suture constitutes greater than about 1% by weight. 
     
     
         28 . An antimicrobial suture according to  claim 1  wherein the proportion of taurolidine in the antimicrobial suture constitutes greater than about 2% by weight. 
     
     
         29 . An antimicrobial suture according to  claim 1  wherein the proportion of taurolidine in the antimicrobial suture constitutes greater than about 6% by weight. 
     
     
         30 . An antimicrobial suture according to  claim 1  wherein the proportion of taurolidine in the antimicrobial suture constitutes greater than about 10% by weight. 
     
     
         31 . An antimicrobial suture according to  claim 1  further comprising barbs. 
     
     
         32 . A method for treating a wound, the method comprising:
 providing an antimicrobial suture comprising at least one filament and taurolidine carried by said at least one filament; and   treating the wound with the antimicrobial suture.   
     
     
         33 . An antimicrobial surgical staple comprising:
 a surgical staple; and   taurolidine carried by said surgical staple.   
     
     
         34 . A method for treating a wound, the method comprising:
 providing an antimicrobial surgical staple, the antimicrobial surgical staple comprising a surgical staple, and taurolidine carried by the surgical staple; and   treating the wound with the antimicrobial surgical staple.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.